Floatz logo

Megestrol Acetate

HIV Wasting Syndrome

Floatz Rating
B63/100
Confidence
Indicative
v0.2
Sponsor
Endo USA Inc., a Keenova Therapeutics Company
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT00637572CT.gov
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
—Completed———
NCT00004664CT.gov
Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting
—Completed———
NCT00000737CT.gov
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
—Completed———
NCT00001079CT.gov
A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · HIV Wasting Syndrome

AssetSponsorPhaseRating
Megestrol Acetate (this asset)Endo USA Inc., a Keenova Therapeutics CompanyP2B · 63
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)P4BB
SerostimEMD SeronoP3B
Testosterone UndecylateNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)P2B
AtazanavirNational Institute of Allergy and Infectious Diseases (NIAID)N/AD
LopinavirNational Institute of Allergy and Infectious Diseases (NIAID)N/AD
Nevirapine AnhydrousNational Institute of Allergy and Infectious Diseases (NIAID)N/AD
NORVIRNational Institute of Allergy and Infectious Diseases (NIAID)N/AD
AbacavirNational Institute of Allergy and Infectious Diseases (NIAID)N/AD

Other indications for Megestrol Acetate

IndicationSponsorPhaseRating
Breast Carcinoma—P4BB · 65
Cancer Of Unknown Primary Site—P3B · 63
Breast Cancer—P3B · 61

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Megestrol Acetate in HIV Wasting Syndrome. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/megestrol-acetate-hiv-wasting-syndrome

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →